Loughborough University
Leicestershire, UK
LE11 3TU
+44 (0)1509 263171
Loughborough University

Loughborough University Institutional Repository

Please use this identifier to cite or link to this item: https://dspace.lboro.ac.uk/2134/14653

Title: Worlds apart? A comparison of the new product development strategies of biopharmaceutical firms in Europe and the USA. Industry and Innovation.
Authors: Xia, Tianjiao
Roper, Stephen
Keywords: Biopharmaceutical
USA
Europe
Comparative analysis
Issue Date: 2009
Publisher: © Taylor & Francis
Citation: XIA, T. and ROPER, S., 2009. Worlds apart? A comparison of the new product development strategies of biopharmaceutical firms in Europe and the USA. Industry and Innovation. Industry and Innovation, 16 (6), pp. 593 - 612.
Abstract: Globally the biopharmaceutical industry is characterized by strong competition, research-intensive and protracted new product development (NPD) processes, intensive regulation and extensive alliance activity. Policy regimes and operating environments differ markedly, however. Here we examine how these differences impact on the NPD strategies of biopharmaceutical firms in the USA and three major EU economies (the UK, France and Germany). Our analysis suggests four key differences between firms' NPD strategies in the two areas. First, while levels of R&D intensity and continuity are broadly similar in the two areas, US firms have notably stronger patent profiles, and are significantly more active in technology licensing than their European counterparts. Second, product development cycles are significantly longer in the USA than among our European respondents. Third, the nature of the product development pipeline is very different in the USA and the major European economies covered by our study: US firms conduct early stage development of more compounds than European firms but take only a similar number to market. Fourth, we see broadly similar levels of alliance activity in our US and European respondents at both the early and late stages of the NPD process. These results suggest a greater substitution of “market” for “hierarchy” in US firms' NPD strategies, reflecting differences in the availability and structure of government support in the USA and Europe.
Description: Closed access. This article was published in the journal, Industry and Innovation [© Taylor & Francis] and the definitive version is available at: http://dx.doi.org/10.1080/13662710903371108
Version: Published
DOI: 10.1080/13662710903371108
URI: https://dspace.lboro.ac.uk/2134/14653
Publisher Link: http://dx.doi.org/10.1080/13662710903371108
ISSN: 1366-2716
Appears in Collections:Closed Access (Business School)

Files associated with this item:

File Description SizeFormat
13662710903371108.pdfPublished version159.17 kBAdobe PDFView/Open

 

SFX Query

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.